Warenius H M, Freedman L S, Bleehen N M
Br J Cancer Suppl. 1980 Apr;4:128-32.
The HT29R human colon adenocarcinoma cell line has been used to investigate the problem of inter-tumour variability in the xenograft system and how this may affect the planning of chemotherapy experiments. Subcutaneous inoculation of 10(6) in vitro cells into immuno-suppressed mice yielded an 80% take rate of moderately poorly differentiated, mucin-secreting tumours with a mean doubling time of 6 days. Statistical estimates from experiments with this system demonstrated that whereas a delay of one doubling time in treated compared with control groups could be detected with relatively small animal numbers, 3 to 4 times as many animals were needed to detect a delay of half a doubling time. The use of 2 tumours per animal yielded the same results as one tumour per animal but reduced the number of animals needed to achieve the same degree of statistical significance.
HT29R人结肠腺癌细胞系已被用于研究异种移植系统中肿瘤间变异性问题以及这可能如何影响化疗实验的规划。将10⁶个体外培养的细胞皮下接种到免疫抑制小鼠体内,产生了80%的接种成功率,形成了中度低分化、分泌粘蛋白的肿瘤,平均倍增时间为6天。该系统实验的统计估计表明,与对照组相比,用相对较少数量的动物就能检测到治疗组中肿瘤倍增时间延迟一倍的情况,但要检测到延迟一半倍增时间则需要3至4倍数量的动物。每只动物使用2个肿瘤与每只动物使用1个肿瘤产生的结果相同,但能减少达到相同统计学显著性程度所需的动物数量。